期刊文献+

某三甲医院恶性肿瘤患者严重药品不良反应分析 被引量:12

Analysis of Serious Adverse Drug Reactions of Patients with Malignant Tumors in a Grade-A Class-3 Hospital
下载PDF
导出
摘要 目的分析恶性肿瘤患者严重药品不良反应(SADR)的特点及相关因素,为临床安全用药提供参考。方法采用回顾性分析法,对医院药品不良反应监测中心2016年收集的恶性肿瘤患者SADR报告进行综合分析。结果 104例SADR报告中,新的SADR 15例(14. 42%);60~69岁年龄段比例最高(27例,25. 96%);累及系统或器官以血液系统居首(53例,28. 49%),临床表现以骨髓抑制最多见;用药途径以静脉滴注为主(80例,76. 92%);使用率前8位药品中化学治疗药物最多,共19例(47. 50%)。结论抗肿瘤药物引起的SADR与患者年龄、剂型、给药途径相关,需充分发挥专科临床药师的作用,集中监测抗肿瘤药物引起的SADR,结合恶性肿瘤患者的自身特点,有目的地进行合理给药,预防或减少SADR的发生。 Objective To analyze the characteristics and related factors of severe drug adverse reactions( SADR) in patients with malignant tumors,and to provide references for clinical safe drug use. Methods Retrospective classification and statistical methods were used to comprehensively analyze the SADR reports collected by the hospital’s Adverse Drug Reaction Monitoring Center in 2016. Results Among the 104 cases of SADR,15 cases( 14. 42%) of new SADRs were reported;the highest proportion was in the 60-69 age group with 27 cases( 25. 96%);the tumor-related system or organ of patients with SADR was the hematological system( 53 cases,28. 49%),and the most common clinical manifestations were bone marrow suppression;the intravenous injection was the main method( 80 cases,76. 92%);chemotherapeutic drugs were the most used among the top 8 drugs,with a total of 19 cases( 47. 50%).Conclusion The SADR caused by anti-tumor drugs is related to age,dosage form and route of administration. It is necessary to give full play to the role of a specialist clinical pharmacist,focus on monitoring the SADR caused by anti-tumor drugs,and combine with the characteristics of patients with malignant tumors to make rational and targeted administration to prevent or reduce the occurrence of SADR.
作者 宁丽娟 苏丹 黄莺 沈爱宗 NING Lijuan;SU Dan;HUANG Yin;SHEN Aizong(Department of Pharmacy,The First Affiliated Hospital of USTC·Anhui Provincial Hospital,Hefei,Anhui,China 230001)
出处 《中国药业》 CAS 2020年第2期40-43,共4页 China Pharmaceuticals
基金 安徽省高等学校省级质量工程项目[2018jyxm0719]
关键词 恶性肿瘤 严重药品不良反应 安全用药 合理用药 malignant tumors serious adverse drug reaction safe drug use rational drug use
  • 相关文献

参考文献9

二级参考文献118

  • 1唐志华,曹国建,丁洁卫.79例药物不良反应报表分析[J].药学实践杂志,2006,24(3):183-184. 被引量:6
  • 2刘丽利,任劼,胡波,邵俊彦.N-乙酰半胱氨酸抢救对乙酰氨基酚中毒1例[J].中国药学杂志,2007,42(18):1438-1439. 被引量:4
  • 3许建明.急性药物性肝损伤诊治建议(草案)[J].中华消化杂志,2007,27(11):765-767. 被引量:350
  • 4PA TEL IN. Application of genotype-guided cancer therapy in solid tumors[J]. Pharmaeogenomies, 2014, 15 ( 1) : 79 - 93.
  • 5SHARMA SV, BELL DW, SETTLEMANJ, et al. Epidermal growth factor receptor mutations in lung cancer[J]. Nature Reviews Cancer, 2007,7(3) :169 -181.
  • 6SHI Y, AUJS, THONGPRASERT S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)[J].J Thorae Oncol , 2014, 9(2) :154 -162.
  • 7LI H, HU H, WANG R, et al. Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients[J]. Oneo Targets Ther,2014, 7:513 -524.
  • 8FUKUOKA M, WU YL, THONGPRASERT S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced nonsmall-cell lung cancer in Asia (iPASS)[J].J Clinilncol ,2011, 29(21) :2866 -2874.
  • 9SOLANGE P, STEFAN Z, ALEX AA. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of nonsmall cell lung cancer: Comparative pharmacokinetics and drugdrug interactions[J]. Cancer Treatment Rev, 2014, 40 ( 8 ) : 917 - 926.
  • 10LIJ, KARLSSON MO, BRAHMERJ, et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors[J].J Natl Cancer Inst ,2006, 98 (23) : 1714 - 1723.

共引文献3518

同被引文献135

引证文献12

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部